YHB Investment Advisors Inc. increased its stake in Stryker Co. (NYSE:SYK) by 1.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,365 shares of the medical technology company’s stock after purchasing an additional 624 shares during the period. Stryker makes up approximately 1.3% of YHB Investment Advisors Inc.’s portfolio, making the stock its 23rd biggest holding. YHB Investment Advisors Inc.’s holdings in Stryker were worth $7,998,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Virtue Capital Management LLC bought a new position in shares of Stryker in the fourth quarter worth approximately $133,000. Bruderman Asset Management LLC purchased a new stake in Stryker in the first quarter worth approximately $152,000. Ostrum Asset Management purchased a new stake in Stryker in the first quarter worth approximately $160,000. Private Capital Group LLC boosted its stake in Stryker by 1,218.4% in the first quarter. Private Capital Group LLC now owns 1,002 shares of the medical technology company’s stock worth $162,000 after buying an additional 926 shares in the last quarter. Finally, Cerebellum GP LLC purchased a new stake in Stryker in the second quarter worth approximately $176,000. Institutional investors own 74.93% of the company’s stock.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction on Friday, May 4th. The stock was sold at an average price of $166.42, for a total value of $832,100.00. Following the completion of the sale, the insider now owns 101,675 shares of the company’s stock, valued at $16,920,753.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Glenn S. Boehnlein sold 750 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $160.00, for a total value of $120,000.00. Following the completion of the sale, the chief financial officer now directly owns 3,535 shares of the company’s stock, valued at approximately $565,600. The disclosure for this sale can be found here. Insiders sold 8,401 shares of company stock valued at $1,389,515 in the last ninety days. 7.30% of the stock is currently owned by insiders.
Several analysts have issued reports on SYK shares. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $192.00 target price for the company in a research note on Monday, May 21st. Canaccord Genuity upped their target price on Stryker from $176.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, April 27th. Stifel Nicolaus upped their target price on Stryker from $183.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday, April 27th. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $170.00 target price on shares of Stryker in a research note on Wednesday, June 13th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $173.95.
NYSE:SYK opened at $173.11 on Monday. The company has a market cap of $64.69 billion, a PE ratio of 26.67, a P/E/G ratio of 2.46 and a beta of 0.70. Stryker Co. has a fifty-two week low of $137.70 and a fifty-two week high of $179.84. The company has a quick ratio of 1.08, a current ratio of 1.64 and a debt-to-equity ratio of 0.64.
Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 26th. The medical technology company reported $1.68 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.08. The firm had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.20 billion. Stryker had a return on equity of 25.65% and a net margin of 8.00%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.48 earnings per share. sell-side analysts anticipate that Stryker Co. will post 7.23 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 31st. Stockholders of record on Friday, June 29th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date of this dividend is Thursday, June 28th. Stryker’s dividend payout ratio (DPR) is presently 28.97%.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.